Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivanisiran for Ocular Pain in Dry Eye Syndrome
NCT02455999Phase 2Completed
- Sponsor
- Sylentis
- Start
- Jun 2015
- Primary completion
- Mar 2016
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of tivanisiran in dry eye syndrome (DED), sponsored by Sylentis. Started Jun 2015; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02455999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02455999.